Gary Rothbard, MD, MS

Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.

Lowering tumor necrosis factor inhibitor dosage by one-third yielded excellent results in terms of safety, clinical effectiveness, and tolerability in patients with rheumatoid arthritis.